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Background: Studies have shown that supply chain costs are a significant proportion of total programme costs.
Nevertheless, the costs of delivering specific products are poorly understood and ballpark estimates are often used
to inadequately plan for the budgetary implications of supply chain expenses. The purpose of this research was to
estimate the country level costs of the public sector supply chain for artemisinin-based combination therapy (ACT)
and rapid diagnostic tests (RDTs) from the central to the peripheral levels in Benin and Kenya.
Methods: A micro-costing approach was used and primary data on the various cost components of the supply
chain was collected at the central, intermediate, and facility levels between September and November 2013.
Information sources included central warehouse databases, health facility records, transport schedules, and expenditure
reports. Data from document reviews and semi-structured interviews were used to identify cost inputs and estimate
actual costs. Sampling was purposive to isolate key variables of interest. Survey guides were developed and
administered electronically. Data were extracted into Microsoft Excel®, and the supply chain cost per unit of
ACT and RDT distributed by function and level of system was calculated.
Results: In Benin, supply chain costs added USD 0.2011 to the initial acquisition cost of ACT and USD 0.3375 to
RDTs (normalized to USD 1). In Kenya, they added USD 0.2443 to the acquisition cost of ACT and USD 0.1895 to
RDTs (normalized to USD 1). Total supply chain costs accounted for more than 30% of the initial acquisition
cost of the products in some cases and these costs were highly sensitive to product volumes. The major cost
drivers were found to be labour, transport, and utilities with health facilities carrying the majority of the cost
per unit of product.
Conclusions: Accurate cost estimates are needed to ensure adequate resources are available for supply chain
activities. Product volumes should be considered when costing supply chain functions rather than dollar value.
Further work is needed to develop extrapolative costing models that can be applied at country level without
extensive micro-costing exercises. This will allow other countries to generate more accurate estimates in the future.
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unless otherwise stated.and Quality Reporting mechanism [1,2]. Although this
transparency has allowed for more accurate cost esti-
mates, supply chain costs for delivering specific prod-
ucts—are still poorly understood and undefined [3,4].
Previous studies demonstrated that supply chain costs
account for a significant proportion of total programme
costs [5-7]. Surveys have found that when measured as
a percentage of the total acquisition cost, supply chain
costs ranged from 1% for contraceptives in Bangladesh
to 13% for essential health commodities in Ghana [8],
18% for ACT in Malawi and up to 44% for large-volume. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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quently determine the budget presented to donors [10]
and are often insufficient for delivering the products to
health facilities. Author analysis of Global Fund pro-
posals during Rounds 8–10 found that between 3 and
14% of total procurement costs are earmarked for pro-
curement and supply chain management (PSM) functions
in Africa [11]. Given that donors are placing a greater em-
phasis on value for money and that commodities consist
about a quarter of all health care costs [12], using accurate
supply chain cost estimates is key to improving access to
medicines and health commodities [13].
Estimating the supply chain costs of a public health
system is complex for several reasons. Most public health
supply chains, particularly those in low- and middle-
income countries, do not systematically track supply chain
costs and rarely keep records on expenditure by each sup-
ply chain function. Additionally, multiple stakeholders in-
cluding donors, government agencies, and international
organizations are responsible for different aspects of the
supply chain. Finally, the supply chain costs are often inte-
grated within other costs and capturing the costs from
each stakeholder, particularly indirect costs, is an onerous
task. Anti-malarial medicines are often distributed using a
combination of malaria-specific supply chains and in-
tegrated systems, which further complicates estimates.
Supply chain costs in each country also depend on the
typology of the system, number of levels in the distri-
bution system, and the types of fixed and variable
costs inherent in the structure [14].
In most malaria-endemic countries, access to ACT and
RDTs for malaria diagnosis and treatment remains well
below targets despite substantial increases in inter-
national disbursements to malaria-endemic countries be-
tween 2002 and 2012. These increases have slowed in
recent years [15,16] and the Global Fund’s new funding
model is placing a greater emphasis on value for money
[17], making better cost estimates even more important.
The objective of this study was to estimate the supply
chain costs for ACT and RDTs from the central to the
peripheral levels of the public sector health systems in
Benin and Kenya. The two countries were selected to
allow for east–west geographical diversity in Africa and
to allow for the anomalies in supply chain design in
Anglophone and Francophone countries. The coun-
tries are also ranked differently on the World Bank lo-
gistics performance index (LPI), a composite estimate
of road network maturity. Benin has an LPI of 2.85,
places 83 out of 155 countries surveyed and is the
highest ranked low-income country. Kenya has an LPI
of 2.43 and ranks 122 out of the 155 countries. In
addition, the SIAPS project presence in both countries
facilitated the logistics associated with data collection
and follow-up.The data collected will help countries to better budget
and plan for these costs. Specifically the study aimed to
accomplish the following:
 Identify the various cost components within the
supply chain functions of procurement, storage,
transportation, and quality control for ACT and
RDTs at each level of the health system, from the
central to the peripheral levels.
 Determine the major cost drivers within the supply
chain functions.
 Allow accurate estimates to be used for programme
planning, budgeting, and policy making decisions.
Mapping the public sector supply chains in Benin and
Kenya for ACT and RDT
Artemether‐lumefantrine (AL) is the first‐line ACT
treatment for uncomplicated malaria in Benin and Kenya
and, together with RDTs, is procured in both countries
using the Global Fund and US President’s Malaria Initia-
tive (PMI) funding. In both countries, supply chains
for ACT and RDTs are integrated within the existing
public sector supply chain. A mapping of the supply
chain structure helped determine how products move
from the central to the peripheral level, and identify and
estimate associated costs. This was done through a com-
bination of Ministry of Health document reviews and in-
terviews with key stakeholders.
Benin
Warehousing and distribution is carried out by La Cen-
trale d’Achat des Medicaments Essentiels et des Consom-
mables Médicaux (CAME), an independent, not-for-
profit organization (Figure 1). Procurement of ACT and
RDTs is done through international procurement agents
and coordinated by the Programme National de Lutte
Contre le Paludisme (PNLP). ACT and RDTs are stored
in a dedicated malaria warehouse and are collected by
zonal depots or sent to one of two regional depots in
Parakou and Natitingou using CAME trucks. Regional
stores pick up their stock from the CAME depots and
health centres and hospitals collect stock from the re-
gional stores. The national hospital, the Centre National
Hospitalier Universitaire (CNHU), and departmental hos-
pitals supply themselves directly from CAME Cotonou.
Product quality control is carried out by the Laboratoire
National de Contrôle de Qualité (LNCQ) upon arrival
in-country and the costs for this are borne by the public
sector.
Kenya
The Kenya Medical Supplies Agency (KEMSA), a para-
statal organization, manages procurement, warehousing,
and distribution of medicines and health products in
Figure 1 Supply chain with volumes and costs (2013 USD) in Benin.
Shretta et al. Malaria Journal  (2015) 14:57 Page 3 of 14Kenya. It also stores and distributes products procured
by other donors directly to health facilities. KEMSA has
two warehouses in Nairobi and since 2013, the county
governments procure commodities directly either from
KEMSA or other suppliers (Figure 2). At the time of this
study, however KEMSA was the central procurement
agency distributing ACT and RDTs to hospitals, health
centres, and dispensaries using a privately contracted
transport provider. The costs thus presented in this
paper represent this structure. The only quality control
costs incurred by the government is post-market surveil-
lance for ACT carried out by the national Pharmacy and
Poisons Board (PPB) in collaboration with the National
Quality Control Laboratory (NQCL) and the Depart-
ment of Malaria Control (DoMC).
Methods
Costing approach
A micro-costing approach was used which included all
fixed and variable costs in the supply chain. Documentreview and semi-structured interviews were carried out
at the central, intermediate, and facility storage levels.
Quantitative information came from financial reports,
KEMSA and CAME databases, distribution records, and
health facility records. Additional information was ob-
tained from logistics reports, transport schedules, expend-
iture and audit reports. When possible, data on actual
rather than budgeted expenditures were used. Extrapola-
tions and inferences were drawn from existing data when
detailed information was not available. Labour costs were
calculated on the basis of self-reported hours. Figure 3
illustrates the approach used.
An application for ethical approval was made to the
University of Michigan Institutional Review Board on
July 10, 2013. A determination of “not regulated status”
was made (eResearch ID: HUM00078395) and on the
basis of this determination, ethical approval was waived
by the appropriate bodies in Benin and Kenya.
Survey guides were developed to facilitate collection of
data on costs of each supply chain function including
Figure 2 Supply chain with volumes and costs (2013 USD) in Kenya.
Figure 3 Supply chain costing overview.
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portation. Cost inputs were identified and included labour,
utilities, security, maintenance, insurance and depreciation
[8]. All costs are reported in 2013 US dollars (USD).
Data collection
Data collection took place between September and No-
vember 2013. A free, open-source software application,
the CommCare® HQ Platform, was used to develop and
administer the electronic survey guides to individuals at
the central, regional and facility levels and aggregate the
data collected.
Sampling
The sites surveyed were selected from Ministry of Health
facility lists. The sampling methodology aimed to reflect
geographic variety, malaria endemicity, rural and urban lo-
cations, accessibility of health facilities, and other factors
that can affect supply chain costs. In addition, sites from
each level of the distribution system were surveyed. The
methodology was not intended to be statistically represen-
tative of the entire country, but rather to isolate the most
relevant elements to this costing exercise.
In Benin, 22 health establishments were selected (six
distribution depots, five hospitals, and 11 health centres)
in three departments of Benin: Atacora, Borgou, and
Littoral-Atlantique. Facilities were chosen within a two-
hour radius of three city centres: Cotonou, Natitingou,
and Parakou. In addition, data were obtained from
CAME and PNLP. Specialized health facilities, national
hospitals, and provincial facilities which did not carry
ACT or RDTs were excluded from the sample. A total of
26 people were interviewed at the central (1), regional
(3), depot (6) and facility (16) levels.
In Kenya, 22 health facilities were selected (six hospi-
tals, seven dispensaries, and nine health centres) within
18 km from a main road in three provinces: Coastal,
Nairobi, and Nyanza. In addition, data were collected at
the three KEMSA warehouses and DoMC. One respond-
ent was interviewed at each of the facilities and two at
the PPB and NQCL level. At the KEMSA level, a team
of respondents provided the information required for
the costing. In both countries respondents were pharma-
cists, pharmacy technicians, nurses, stock managers or
clinicians.
Annual throughput
Data on the total volume of products moving through
the entire supply chain over the course of one year or
annual throughput were collected from KEMSA and
CAME using shipment history and procurement status
reports from July 2012 through June 2013. This included
donor procurements. The annual volume and value of
products was estimated by multiplying the number ofeach stock-keeping unit (SKU) by the volume of each
unit in cubic metres and the unit price and summing
across all products. SKUs of the four ACT packs were
included in the analysis (blister packs of 6, 12, 18, and
24 tablets) in addition to RDT kits. In all cases, “ACT”
refers to AL in Kenya and Benin.
Cost categories
Costs for management and administration including any
maintenance and information technology (IT) costs were
integrated into the functions and not considered as a
separate category.
Procurement costs
Procurement expenses included costs of forecasting, ten-
der development, management, and award. Inputs in-
cluded labour costs for developing the forecast, bid
evaluation, and award as well as costs for advertising
tenders in the local media. Annual procurement costs in
both Benin and Kenya were calculated by dividing the
ACT or RDT tenders by the total number of tenders.
The resulting figure was multiplied by the annual cost of
the tendering process and divided by the total units of
ACT and RDTs, respectively. When products were fi-
nanced by PMI, they were procured directly through
USAID | DELIVER and the government did not incur
any procurement cost.
Product quality control costs
Quality control costs were mainly associated with the
collection and testing of products. In Benin, samples
from each product batch of ACT were tested upon ar-
rival in the country. LNCQ charges PNLP a fee for
testing each batch. Costs were, therefore, calculated
according to the number of batches arriving in the
country.
In Kenya, the supplier conducts pre-shipment inspec-
tion and this cost was, therefore, not included in the es-
timates. The only costs for quality testing of ACT were
from post-marketing surveillance activities carried out at
select sites using a Minilab®. The total cost for this activ-
ity was readily available from PPB. Secondary testing,
when necessary was performed by NQCL which charged
a standard price per sample.
Storage costs
Storage costs included fixed (e.g. infrastructure equip-
ment) and recurrent costs (e.g. utilities, rent, equipment
maintenance, stock management, labour, insurance,
security, and other administrative expenses). It also
included the costs associated with depreciation of
equipment, IT, and warehouses and their potential
replacement value. Storage costs per unit were calcu-
lated according to the total cost figures provided by
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tributed that year.
Transportation costs
Transportation costs included labour costs for staff, de-
preciation of vehicles, fuel, repairs, maintenance, and in-
surance. Costs were classified as transportation if the
cost was associated with the delivery or pick-up from a
storage facility. In Benin, CAME Cotonou made quar-
terly shipments to its depots in Parakou and Natitingou
and staff used health facility vehicles or public transport
to obtain commodities from these central tiers. ACT and
RDTs were shipped separately and associated costs were
easily calculated using the above inputs. In Kenya, trans-
port was subcontracted and these costs were readily
available from KEMSA. Shipments were made quarterly
and the costs attributable to ACT and RDTs were esti-
mated according to the volume of space occupied in a
standard truck.
Labour costs
Labour costs for supply chain-related tasks were calcu-
lated based on self-reported hours during the interview
process by staff responsible for managing malaria com-
modities. Each staff member’s civil service grade was
matched to the public service management salary guide
to obtain labour costs.
Data analysis
Our primary objective was to estimate the supply chain
costs per unit of ACT or RDT distributed. In all cases a
unit was ACT was one treatment course packaged in a
single unit pack and a single RDT. This cost was calcu-
lated by dividing the annual PSM costs by the annual
throughput of all commodities. Throughput was esti-
mated by function, input type, and level of the supply
chain. Cost and throughput were expressed in 2013
USD, using an average exchange rate of 494.11 Benin
Central African francs and 84.76 Kenyan shillings [18].
The aggregate supply chain cost per unit from the na-
tional store to service delivery level was calculated as
follows:
Aggregate supply chain cost per unit = [cost per unit
at the Central Medical Store (CMS)] + [average cost per
dose at intermediate tier(s)] + [average cost per unit for
the health centres and hospitals].
Unit costs of ACT and RDTs at health facilities were
also calculated. From these, an average cost was derived
by taking each facility cost and weighting it to the num-
ber of ACT and RDTs procured by that health facility.
This cost was then divided by the median MXð Þ volume
procured and multiplied by the volume of a treatment
or test (vACT) to obtain per unit cost for ACT or RDTs.For example, for labour costs per ACT, for every health
centre or hospital “i” the formula is represented as follows:
ΣðLabor Costi  Total ACT Units ProcurediÞ=
Σ Total ACT Units Procuredið Þ
MX Total Volume Procuredið Þð Þ  vACT
This calculation was made for each of the other costs:
utilities, labour, transportation, security, and depreci-
ation of IT, equipment, and warehouses.
Volumes in cubic metres for each SKU were ob-
tained from KEMSA. Equivalent data were not avail-
able in Benin, and therefore KEMSA volumes were
used for identical products. For products distributed
in Benin that were not stocked by KEMSA, standard
volume data for products from the USAID | DELIVER
project were used [19]. When data were not otherwise
available, proxy volumes from products with similar
volumes were used.
The replacement costs for the government-owned
storage facilities, associated buildings, and fixed assets
(e.g., vehicles and equipment) were estimated using
straight-line depreciation. Staff and the portion of other
resources allocated specifically to ACT and RDTs were
identified. Where this information was not available,
weighted averages were used to apportion the costs spe-
cifically to these products.
Most health facilities perform mainly clinical activities;
therefore the administrative function of a facility covered
several other non–logistics-related functions. The cost
of administrative supply chain activities at the health fa-
cility level was estimated to be 10% of total administra-
tive operating costs. For clinics, 50% of operating costs
were apportioned to storage activities. In Benin, zonal
depots were dedicated to storage activities and, there-
fore, incurred 100% of operating costs. Similarly, CAME
warehouses had spaces dedicated to anti-malarials and
hence also incurred 100% of the related expenditures.
The various cost drivers in each of the four functions
were assessed to determine if one function accounted
for a large proportion of costs relative to the others, and
how changes in the quantity or volume of goods passing
through the system affected each function. Depending
on the nature of the supply chain function, either
volume-proportional or value-proportional cost allo-
cations were used. In the volume-proportional cost
allocation method, the fixed costs and overhead costs
were allocated to the products in proportion to the
relative volume in quantity or cubic metre. In the
value-proportional cost allocation method, the fixed
costs and overhead costs were allocated to malaria
commodities in proportion to the monetary value of the
products. Volume-proportional cost allocation, as mea-
sured by the quantity of product, was used to allocate
costs related to procurement (tender management) and
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cost for quality assurance activities. To determine this per
unit cost, the total yearly cost of testing ACT was divided
by the total number of units shipped from KEMSA for
that same year normalized to USD1. Storage and transport
functions were analyzed using volume-proportional cost
allocation in cubic metres. Value-proportional cost alloca-
tion was used only to estimate insurance costs.
Given the uncertainty in the cost estimates, the stand-
ard deviation (SD) from the mean weighted costs was
calculated [see Additional files 1 and 2].
Results
Annual throughput
In Kenya, KEMSA delivered a total volume of 18,441
cubic metres of ACT and RDTs from July 2012 to June
2013 including 14,979,359 treatments of AL and
7,277,960 individual RDT tests. A median of 1,827 treat-
ment courses of ACT was distributed to each facility,
which made up 9% of total volume distributed by
KEMSA. RDTs represented 2% of total volume of prod-
uct distributed. The total value distributed was USD
17,292,353 of ACT and USD 5,153,328 of RDTs (calcu-
lated from PMI landed cost per RDT and Global Fund
price quality reporting cost per treatment).
In Benin, the exact volumes of commodities were un-
known at the lower tiers - a value required to calculate
supply chain cost by tier hence, simple heuristics were
used to develop estimates of product flow volume as fol-
lows. Using data provided by CAME on the total quan-
tity of pharmaceuticals and anti-malarials shipped to the
regional warehouses and zonal depots and knowledge of
the supply chain network illustrated in Figure 1, it was
determined that depots represented 12% of the demand
for CAME’s general pharmaceutical products and 94%
and 98% for ACT and RDTs, respectively. Among the
depots, ACT represented 0.7% of total volume and RDTs
represented 0.02% of total volume procured from CAME
Cotonou. To determine the total volume procured from
the CAME warehouses in Parakou and Natitingou, the
average proportion of ACT and RDTs to total volume of
all commodities was used. Using the number of health
centres and hospitals serviced by each province and
known demand data from a hospital and health centre
in Cotonou, it was determined that 30% of depot volume
went to hospitals and 70% of volume was split across
other health centres. The total value of ACT distributed
between July 2012 and June 2013 was USD 377,258;
the total value for RDTs was USD 224,800. These were
based on the unit value calculated from PMI total
acquisition costs multiplied by quantity of products
distributed.
Figures 1 and 2 illustrate the throughput and unit
costs within the supply chain structure in Benin andKenya. In each chart, the volumes represent the distribu-
tion flow to each storage facility over the course of one
year. Calculations were made according to the average
volumes distributed to the facilities from the sample.
Values of ACT and RDT are the distribution costs for
each tier per unit in USD (2013) normalized to USD 1.
Total supply chain costs
Total costs were analyzed by level, function, and cost
category. This section summarizes the cost and cost
drivers, and determines how sensitive distribution costs
are to changes in a product’s acquisition cost.
Central-level costs
The main central-level procurement costs incurred were
for tender management and advertising. In both Benin and
Kenya, the national quality control laboratories charged the
malaria programmes for each batch tested.
Total costs for tendering in Benin amounted to USD
2,819 for ACT for 2012–2013. RDTs were procured
through PMI and, therefore, incurred no procurement
charges to the government. USD 160 was charged per
batch of ACT and USD 200 per batch of RDTs for a total
annual cost of USD 648 and USD 2,024 for quality test-
ing of ACT and RDTs, respectively.
In Kenya, procurement costs for tender management
amounted to USD 13,998 for ACT and USD 4,666 for
RDTs. and the total cost for post-marketing surveillance
of ACT in the public sector was USD 3,749. RDTs were
not tested and, therefore, did not incur a cost.
Central storage and distribution level costs
In Benin, central-level storage and distribution costs for
ACT and RDTs from CAME Cotonou were estimated at
a total of USD 26,163. To transport ACT and RDTs
along with antiretrovirals to regional warehouses in
Parakou and Natitingou, the cost was USD 1,821 per
trip. Four trips were made during the assessment year,
and ACT and RDTs made up an estimated two-thirds of
the volume transported for a total annual transportation
cost of USD 4,857. Regional depots incurred an annual
cost of USD 21,014 to store ACT and RDTs. At KEMSA,
central-level management costs for ACT and RDTs were
USD 249,675. The annual cost to transport ACT and
RDTs by a third-party contractor directly to health facil-
ities was USD 440,210.
Peripheral-level storage and distribution costs
In Benin, the median annual operating cost across de-
pots was USD 8,394, across hospitals was USD 14,788,
and across clinics was USD 4,755. In Kenya, the median
operating cost for annual storage of all commodities was
USD 15,288 at hospitals and USD 13,054 at clinics.
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cost by the total quantity distributed.
Supply chain costs per unit of ACT and RDT distributed
Using data from each distribution tier, the total supply
chain costs of ACT and RDTs were estimated. Prices
were normalized to USD 1 of product flowing through
the distribution channel for simple comparison.
Tables 1, 2, 3 and 4 and Figures 4, 5, 6, and 7 illustrate
the cumulative supply chain costs for distribution of
ACT and RDTs from the central level to the peripheral
level normalized to USD 1. In Benin, supply chain costs
added USD 0.2011 (SD = 0.1216) to the initial acquisi-
tion cost of ACT and USD 0.3375 (SD = 0.1544) to the
cost of RDTs.
In Kenya, supply chain costs added USD 0.2443 (SD =
0.0183) to the acquisition cost of ACT and USD 0.1895
(SD = 0.0471) for RDTs. When these values were calcu-
lated as percentages of the landed cost of ACT and
RDTs in the respective countries, the percentage values
obtained were 20% for ACT and 34% for RDTs in Benin
and 24% for ACT and 19% for RDTs in Kenya. In both
countries and across both products, the highest costs
were incurred during the “last mile” of distribution at
the health facility. Across the functions, labour, transpor-
tation and utilities incurred the highest costs, particu-
larly at the health facility level.
A sensitivity analysis performed on the acquisition
costs of ACT and RDTs in both countries against the
percentage contribution of the supply chain (Figure 8) il-
lustrated the volatility and inaccuracy of estimating the
distribution cost as a percentage of the initial acquisition
cost. This high sensitivity was due to the association of
over 99% of costs to the volume of the product distrib-
uted. The only distribution cost directly dependent on
product value was commodity insurance which was low
relative to other costs.Table 1 Unit costs for ACT in Benin
Central level CMS Regio
Product quality testing $ 0.0017 $ - $ -
Announcements in local media $ 0.0005 $ - $ -
Insurance for commodities $ - $ 0.0000 $ -
Utilities $ - $ 0.0008 $ 0.00
Labour $ 0.0069 $ 0.0369 $ 0.02
Security $ - $ 0.0001 $ 0.00
Other SG & A $ - $ 0.0000 $ 0.00
Maintenance $ - $ 0.0001 $ 0.00
Rent - Warehouse $ - $ - $ -
Depreciation $ - $ 0.0013 $ 0.00
Transport $ - $ - $ 0.00
Total $ 0.0092 $ 0.0393 $ 0.03Disaggregating hospitals and health centres and urban
and rural facilities
Hospital and health facility costs were disaggregated by
estimating the respective costs and weighting them to
the total number of each facility type. The resulting esti-
mate was a lower per unit of product than when hospi-
tals and health centres were aggregated. In Benin, the
resulting distribution cost was 14% of acquisition cost
for ACT and 26% for RDTs and 13% and 10% for ACT
and RDTs in Kenya. In both Benin and Kenya, the per-
unit cost of storage at health clinics was much higher
than at hospitals. Even though the overall operating
costs of a hospital were higher in Kenya, the per unit
cost for storing ACT at health clinics was approximately
six times higher than at hospitals due to the lower vol-
ume of products stored at health centre level. Similarly,
storage costs for RDTs were three times higher at health
clinics than those incurred at hospitals.
Additionally, costs by rural and urban facilities were
also disaggregated. Operating costs were approximately
1.5 times higher in rural facilities than urban ones while
transport costs were up to 40% higher in rural facilities.
Furthermore, the volume procured by urban facilities
was five times greater than rural facilities with 30% more
ACT and RDTs than rural facilities. In both countries,
disaggregating the urban and rural facilities decreased
the supply chain cost estimate in urban facilities to 10%
and 23% in Benin and 23 and 19% in Kenya for ACT
and RDTs. A smaller difference was obtained between
urban and rural facilities in Benin.
Major cost drivers
The median annual labour cost for depots was USD
3,155, USD 3,226 for hospitals, and USD 1,918 for
clinics. Labour was the highest cost contributor at all
levels accounting for on average 62% of total supply
chain costs. Although salaries themselves are notnal warehouse Zonal store All health facilities Total
$ - $ - $ 0.0017
$ - $ - $ 0.0005
$ - $ - $ 0.0000
04 $ 0.0016 $ 0.0472 $ 0.0501
98 $ 0.0024 $ 0.0386 $ 0.1147
06 $ 0.0001 $ 0.0080 $ 0.0089
00 $ - $ - $ 0.0000
01 $ - $ - $ 0.0002
$ - $ - $ -
06 $ 0.0019 $ 0.0145 $ 0.0184
27 $ 0.0002 $ 0.0037 $ 0.0066
43 $ 0.0062 $ 0.1120 $ 0.2011
Table 2 Unit costs for RDTs in Benin
Central level CMS Regional warehouse Zonal store All health facilities Total
Product quality testing $ 0.0090 $ - $ - $ - $ - $ 0.0090
Announcements in local media $ - $ - $ - $ - $ - $ -
Insurance for commodities $ - $ 0.0000 $ - $ - $ - $ 0.0000
Utilities $ - $ 0.0019 $ 0.0010 $ 0.0036 $ 0.0568 $ 0.0634
Labour $ - $ 0.0856 $ 0.0692 $ 0.0056 $ 0.0521 $ 0.2125
Security $ - $ 0.0003 $ 0.0015 $ 0.0003 $ 0.0111 $ 0.0132
Other SG & A $ - $ 0.0001 $ 0.0000 $ - $ - $ 0.0001
Maintenance $ - $ 0.0003 $ 0.0002 $ - $ - $ 0.0005
Rent - Warehouse $ - $ - $ - $ - $ - $ -
Depreciation $ - $ 0.0030 $ 0.0014 $ 0.0025 $ 0.0214 $ 0.0283
Transport $ - $ - $ 0.0063 $ 0.0004 $ 0.0038 $ 0.0104
Total $ 0.0090 $ 0.0912 $ 0.0795 $ 0.0125 $ 0.1453 $ 0.3375
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be attributed to large number of employees or potential
lower productivity. Utilities were the second largest cost
driver, accounting for about 20% of cost followed by
transportation at 12% of cost. The primary utility cost
was electricity, and the primary cost driver for transport
was fuel, which amounted to over 20% of total transpor-
tation cost. Utility costs were higher in Benin than
Kenya whereas the reverse was true for labour costs.
Thus, proportionally, utility costs appear to be signifi-
cantly more in Benin. Figure 9 illustrates the cost drivers
for ACT and RDTs in Benin and Kenya.
Discussion
This study identified the structural and operational sup-
ply chain costs associated with distribution of ACT and
RDTs in Benin and Kenya. The cost of procurement, dis-
tribution, and product quality control was estimated
using an output metric of cost per USD value of an
ACT and RDT unit distributed. Other studies have usedTable 3 Unit costs for in Kenya
Cost categories Central level
Product quality testing $ 0.0003
Announcements in local Media $ 0.0002
Insurance for commodities $ -
Utilities $ -
Labour $ 0.0006
Security $ -
Other SG & A $ -
Maintenance (IT and equipment) $ -
Rent - Warehouse $ -
Depreciation $ -
Transport $ -
Total $ 0.0011a variety of cost metrics: costs per USD value [20-22];
costs per kilogram [22], and costs per kilometre [20-22].
These studies estimated costs to be USD 0.63–1.15 for
vaccines in Mozambique [21], USD 0.24–2.00 for gen-
eral products in Nigeria [20]; and 7.6–24% for antiretro-
virals, essential medicines and vaccines in Zambia,
Uganda and Niger, respectively [23-25].
The findings indicate that supply chain costs play a
significant role in the total cost of delivering ACT and
RDTs. A few cost drivers stand out in both Benin and
Kenya - labour, transport, and utilities. At the level of
storage, labour and utilities stand-out accounting for up
to 71% of the total distribution costs of ACT in Kenya.
It should be noted that labour cost estimates for ACT
and RDT stock-management were based on self-
reported hours during interviews with heath workers, a
process likely to be associated with reporting bias. How-
ever, despite this, these findings are consistent with
those from other studies [22,23,25], although in the case
of vaccines, high cold chain and equipment costs makeCMS All health facilities Total
$ - $ - $ 0.0003
$ - $ - $ 0.0002
$ 0.0000 $ - $ 0.0000
$ 0.0011 $ 0.0057 $ 0.0067
$ 0.0103 $ 0.1615 $ 0.1724
$ 0.0001 $ 0.0132 $ 0.0133
$ 0.0010 $ - $ 0.0010
$ 0.0004 $ 0.0010 $ 0.0014
$ 0.0001 $ - $ 0.0001
$ 0.0006 $ 0.0186 $ 0.0192
$ - $ 0.0298 $ 0.0298
$ 0.0134 $ 0.2298 $ 0.2443
Table 4 Unit costs for RDTs in Kenya
Product quality testing $ - $ - $ - $ -
Announcements in local Media $ 0.0002 $ - $ - $ 0.0002
Insurance for commodities $ - $ 0.0000 $ - $ 0.0000
Utilities $ - $ 0.0008 $ 0.0058 $ 0.0066
Labour $ 0.0007 $ 0.0077 $ 0.1222 $ 0.1306
Security $ - $ 0.0000 $ 0.0103 $ 0.0103
Other SG & A $ - $ 0.0007 $ - $ 0.0007
Maintenance (IT and equipment) $ - $ 0.0003 $ 0.0003 $ 0.0005
Rent - Warehouse $ - $ 0.0001 $ - $ 0.0001
Depreciation $ - $ 0.0004 $ 0.0177 $ 0.0181
Transport $ - $ - $ 0.0223 $ 0.0223
Total $ 0.0009 $ 0.0100 $ 0.1785 $ 0.1895
Shretta et al. Malaria Journal  (2015) 14:57 Page 10 of 14total supply chain costs higher and, therefore, labour be-
comes a smaller percentage of total supply chain costs
(Lydon et al. 2014 [3]). In addition, labour costs may be
co-funded by the countries themselves and often not in-
cluded in proposals to donors. The costs in this paper,
however, represent the total resources that countries are
dedicating to distribution.
The analysis also established that supply chain costs
per ACT unit varied by the level of the system with costs
increasing as the product reaches the last mile. In both
countries, despite having very different health system
structures, the costs tended to be the highest at the level
of the health centre or dispensary in comparison to the
central or intermediate storage depots. A further break-
down of the health facilities by hospitals and primary
health clinics illustrated that health clinics were much
more expensive than hospitals for supply chain functions
per unit of product. Although the overall operating costs
of a hospital were higher, clinic storage costs wereFigure 4 ACT cost breakdown normalized to USD 1 (2013)
in Benin.approximately six times the cost of storage at hospitals
for ACT and three times for RDTs mostly due to the
higher volume of ACT and RDTs flowing through
hospitals. These findings are consistent with those from
other studies [7,21,25,26]. Central storage costs for anti-
malarials were much higher in Benin possibly due to the
use of dedicated warehouses and labour for their man-
agement. Similarly in Kenya, operating costs were found
to be about three times higher for ACT and RDTs in
rural facilities than urban ones. The total volume pro-
cured by urban facilities was five times greater than that
procured by rural facilities and higher transport costs to
rural facilities may play a part in this observation.
The findings also illustrated the importance of product
volumes as measured by product dimensions in estimat-
ing costs of the supply chain. A greater portion of the
storage costs are fixed and reliant on volume; therefore,
when considering the costs attributed to a unit of product,
as volume increases, costs proportionately decrease. In theFigure 5 RDT cost breakdown normalized to USD 1 (2013)
in Benin.
Figure 6 RDT cost breakdown normalized to USD1 (2013)
in Kenya.
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the batch size tested. Cost per unit of product will therefore
stay relatively stable despite fluctuation in total volume.
The study provided evidence that using a percentage of the
acquisition costs to estimate supply chain costs can be in-
accurate. This has major implications for the way costs for
procurement and SCM are currently estimated. These find-
ings indicate that using “ballpark” percentages to estimate
supply chain costs, may cause shortfalls in resource alloca-
tions for supply chain functions. Countries should be sup-
ported to generate more accurate estimates in the future.
The authors note that the costs described in this study
are for the existing public sector supply system, includ-
ing current inefficiencies [27-30]. This work does not
separate inefficiencies but rather builds them into theFigure 7 RDT cost breakdown normalized to USD 1 (2013)
in Kenya.cost analysis. The study does not identify such inefficien-
cies in the system, create an optimization model or sug-
gest what an ideally operating system should cost. Doing
so would require additional data and analysis on service-
level indicators including product availability, quality,
and price. While this work moved costing closer toward
transparency and accuracy, it is only a glimpse of supply
chain operations Kenya and Benin. A more complete
picture needs routine data collection with sufficient
time-lapsed data points to allow statistical conclusions
to be made. In addition to greater cost transparency, this
could lead to a richer understanding of operational
needs. This cost data however provides valuable infor-
mation for these additional analyses including informa-
tion for economic evaluations.
This study has a few limitations. Although the propor-
tional cost of the supply chain was obtained in this re-
search, it is specific to the ACT and RDTs in distributed
in Benin and Kenya. These percentages are not to be ap-
plied generally by a CMS across all the products of vary-
ing value and volume. Two additional considerations
that should be made are time allocation, which is the
driving force behind labour cost, and specific distribu-
tion requirements, such as those for a cold chain. Sec-
ondly, the sampling methodology was not intended to be
statistically representative of the entire country but was
rather directed at identifying the key variables that may
influence supply chain cost which may have introduced
a level of selection bias.
While an accurate costing of the supply chain is im-
portant for budgeting and planning, conducting a micro-
costing exercise is a highly resource- and time-intensive
effort. Given that the supply chain costs vary according
to the acquisition cost, a better methodology is needed
for estimating costs rather than using a fixed percentage.
Three options should be considered in place; one option
is to use different weights for the costs of the supply
chain for high and low-value products. A second option
would be to use algorithms of different handling fees
based on budget line items [10], which would entail sep-
arating products and allocating different proportions to
each group. Lastly, the authors recommend using a sim-
ple extrapolative model to estimate distribution costs at
country level. This remains a priority for researchers and
implementers working in this arena.
Conclusion
Unpacking the supply chain costs has several advantages.
First, countries and donors can identify the major cost
drivers where a more in-depth analysis may be required to
identify opportunities for improved efficiency particularly if
major discrepancies between similar countries are found.
Second, it allows donors and countries to separate the
costs for the supply chain tiers and functions and allows
Figure 8 Sensitivity analysis on distribution cost as a percent of acquisition cost.
Figure 9 Breakdown of cost drivers for ACT and RDTs in Benin and Kenya.
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ation of costs. Third, it allows countries to demonstrate
how government funds are being leveraged for procure-
ment and SCM functions in proposals. The study provided
information that can be used by policymakers to under-
stand the costs of the supply chain for ACT and RDTs and
to advocate for the efficient allocation of resources for fu-
ture programme needs.
In conclusion, product volumes should be considered
when costing distribution rather than value. Countries
should avoid using percentages of total acquisition costs
to estimate the cost of product distribution, and plan-
ners and policy makers can use the information on cost
drivers to conduct a more detailed analysis to determine
how to increase efficiency. Given that countries should
use accurate distribution cost data when budgeting for
malaria interventions and that costing studies are expen-
sive and time-intensive, a model to generate more accur-
ate estimates in the future, by estimating costs according
to volume rather than value would be embraced by
stakeholders. Furthermore, additional country-level stud-
ies are needed to capture country-specific costs and to
draw inferences across different supply chain structures.
Additional files
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Normalized to USD 1).
Additional file 2: Uncertainty analysis for Kenya (Costs in USD 2013
Normalized to USD 1).
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